STANDARD BIOTOOLS INC.
About STANDARD BIOTOOLS INC.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $85.3M
- Net income
- -$74.9M
- Total assets
- $567.8M
- Market cap
- $448.9M
- Gross margin
- 49.9%
- Operating margin
- -129.2%
- Net margin
- -87.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $85.3M
- Cost of revenue
- $42.8M
- Gross profit
- $42.5M
- Operating expenses
- $152.8M
- Operating income
- -$110.2M
- Income tax
- -$37.9M
- Net income
- -$74.9M
- EPS (basic)
- $-0.20
- EPS (diluted)
- $-0.20
Balance sheet
- Total assets
- $567.8M
- Current assets
- $454.3M
- Total liabilities
- $143.5M
- Current liabilities
- $108.3M
- Shareholders’ equity
- $424.3M
Cash flow
- Operating cash flow
- -$74.3M
- Investing cash flow
- $27.4M
- Financing cash flow
- $570.0K
- Net cash flow
- -$45.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $448.9M
- EPS (diluted)
- $-0.2
- Shares outstanding
- 561.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 10, 2011
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $74.9M in FY2025.
- Revenue declined 13% from FY2022 to FY2025.
- Gross margin of 49.9%, net margin -87.8%.
- Trading 52% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review STANDARD BIOTOOLS INC..
Write a review
News about STANDARD BIOTOOLS INC.
News & sentiment via Polygon.io
